Cannabis Big News Roundup: Koios Mapping Human Brain to Study Impact of CBD; Matica and Yunify Develop First Consumer Product; Cannvas Signs Revenue Share and Marketing Agreement with MOOD™

November 9 2018 by cranbak in News |Comments Off on Cannabis Big News Roundup: Koios Mapping Human Brain to Study Impact of CBD; Matica and Yunify Develop First Consumer Product; Cannvas Signs Revenue Share and Marketing Agreement with MOOD™

In case you missed it, here is this week’s big news roundup for cannabis: Bougainville Signs Binding LOI to Acquire Assets of Gene Bank Research Inc. Invictus and Poda Announce Closing of Arrangement Pure Global Cannabis Launching Medical Product Line With Research Driven Approach Koios Mapping Human Brain to Study Impact of CBD 1933 Industries […]

Koios Mapping Human Brain to Study Impact of CBD

November 8 2018 by cranbak in News |Comments Off on Koios Mapping Human Brain to Study Impact of CBD

Koios Beverage (CSE:KBEV, OTC:SNOVF)  (the “Company” or “Koios”), is pleased to announce the Company will be initiating a clinical study into the impact of CBD on the human brain. Koios is already conducting a clinical trial on the impact of its nootropic supplements on the human brain, and released preliminary results on Oct. 9, 2018. Koios […]

Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules

August 1 2018 by cranbak in News |Comments Off on Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, is pleased to report significant bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBDTM – a proprietary, DehydraTECH powered, cannabidiol (“CBD”) fortified hemp oil capsule developed by Lexaria. The degree and speed of CBD absorption […]